Advance Search
FENG Ting, QU Ying, LIU Lian, WANG Lin. Incidence and severity grading of treatment-related adverse event associated with programmed death-1/programmeddeath-ligand 1 inhibitors combined with various anticancer regimens[J]. Journal of Clinical Medicine in Practice, 2025, 29(2): 19-23. DOI: 10.7619/jcmp.20244644
Citation: FENG Ting, QU Ying, LIU Lian, WANG Lin. Incidence and severity grading of treatment-related adverse event associated with programmed death-1/programmeddeath-ligand 1 inhibitors combined with various anticancer regimens[J]. Journal of Clinical Medicine in Practice, 2025, 29(2): 19-23. DOI: 10.7619/jcmp.20244644
shu

Incidence and severity grading of treatment-related adverse event associated with programmed death-1/programmeddeath-ligand 1 inhibitors combined with various anticancer regimens

  • 1.

    Department of Western Pharmacy, the Affiliated Hospital of Chengdu University, Chengdu, Sichuan, 610081

  • 2.

    Department of Pharmacy, the Seventh People's Hospital of Chengdu, Cancer Hospital Affiliated to Chengdu Medical College, Chengdu, Sichuan, 610213

More Information
  • Received Date: October 07, 2024
  • Revised Date: December 16, 2024
    Graphical Abstract
    • Abstract
  • Objective 

    To analyze the incidence and severity grading of treatment-related adverse event (TRAE) associated with programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) inhibitors combined with various anticancer regimens.

    Methods 

    A total of 356 tumor patients treated with PD-1/PD-L1 inhibitors were retrospectively selected as the study objects. The occurrence of adverse reactions in patients treated with PD-1/PD-L1 inhibitors combined with different anticancer regimens was recorded and analyzed.

    Results 

    Among the 356 patients treated with PD-1/PD-L1 inhibitors in combination with various anticancer regimens, 332 times of TRAEs were observed. Fatigue and adverse gastrointestinal reactions were the most prevalent, accounting for 31.93% (106/332) and 20.78% (69/332) respectively. Skin-related adverse reactions (appearing within 3 to12 weeks) and gastrointestinal adverse reactions (5 to 10 weeks) occurred first, while fever (10 to 30 weeks) and pneumonia (12 to 32 weeks) presented later, with the longest observation time span. The lowest overall incidence of TRAE was observed in the combination of PD-1/PD-L1 inhibitors with cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitors (85.71%, 36/42), while the highest was in the combination with platinum-based doublet chemotherapy (96.88%, 155/160). The incidence of grade 3 to 5 TRAEwas lowest in the combination of PD-1/PD-L1 inhibitors with radiotherapy (10.53%, 6/57) and highest in the combination with vascular endothelial growth factor/vascular endothelial growth factor receptor (VEGF/VEGFR) targeted therapy (44.64%, 25/56). There was no significant difference in the incidence and severity of TRAE among different tumors (P>0.05).

    Conclusion 

    When different anti-cancer regiments combined with PD-1/PD-L1 inhibitors, the overall incidence of TRAE is higher, among which the incidence of TRAE combined with CTLA-4 is relatively lowest, and the symptoms of TRAE combined with radiotherapy are relatively mild.

    • FullText(HTML)
    • References (22)
  • [1]
    CAO W, CHEN H D, YU Y W, et al. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020[J]. Chin Med J, 2021, 134(7): 783-791. doi: 10.1097/CM9.0000000000001474
    [2]
    SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. doi: 10.3322/caac.21660
    [3]
    LI C M, HARATIPOUR P, LINGEMAN R G, et al. Novel peptide therapeutic approaches for cancer treatment[J]. Cells, 2021, 10(11): 2908. doi: 10.3390/cells10112908
    [4]
    PATEL S A, NILSSON M B, LE X N, et al. Molecular mechanisms and future implications of VEGF/VEGFR in cancer therapy[J]. Clin Cancer Res, 2023, 29(1): 30-39. doi: 10.1158/1078-0432.CCR-22-1366
    [5]
    WU Q, QIAN W, SUN X L, et al. Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021[J]. J Hematol Oncol, 2022, 15(1): 143. doi: 10.1186/s13045-022-01362-9
    [6]
    FREITES-MARTINEZ A, SANTANA N, ARIAS-SANTIAGO S, et al. Using the common terminology criteria for adverse events (CTCAE-version 5. 0) to evaluate the severity of adverse events of anticancer therapies[J]. Actas Dermosifiliogr, 2021, 112(1): 90-92. doi: 10.1016/j.ad.2019.05.009
    [7]
    LUO F R, DING J, CHEN H X, et al. Breakthrough cancer medicine and its impact on novel drug development in China: report of the US Chinese Anti-Cancer Association (USCACA) and Chinese Society of Clinical Oncology (CSCO) Joint Session at the 17th CSCO Annual Meeting[J]. Chin J Cancer, 2014, 33(12): 620-624.
    [8]
    MAGGIORE U, PALMISANO A, BUTI S, et al. Chemotherapy, targeted therapy and immunotherapy: which drugs can be safely used in the solid organ transplant recipients?[J]. Transpl Int, 2021, 34(12): 2442-2458. doi: 10.1111/tri.14115
    [9]
    YI M, ZHENG X L, NIU M K, et al. Combination strategies with PD-1/PD-L1 blockade: current advances and future directions[J]. Mol Cancer, 2022, 21(1): 28. doi: 10.1186/s12943-021-01489-2
    [10]
    CHEN Y X, LIU Y Z, WANG Y, et al. Prevotellaceae produces butyrate to alleviate PD-1/PD-L1 inhibitor-related cardiotoxicity via PPARα-CYP4X1 axis in colonic macrophages[J]. J Exp Clin Cancer Res, 2022, 41(1): 1. doi: 10.1186/s13046-021-02201-4
    [11]
    孙颖丽, 刘一, 任晓蕾, 等. 信迪利单抗治疗胃癌致甲状腺免疫相关不良反应的单中心回顾性研究[J]. 临床药物治疗杂志, 2024, 22(3): 38-42.
    [12]
    周潇翔. 抗PD-1/PD-L1免疫治疗的不良反应谱及其预测标志物探究[D]. 北京: 北京协和医学院, 2021.
    [13]
    RAMOS-CASALS M, BRAHMER J R, CALLAHAN M K, et al. Immune-related adverse events of checkpoint inhibitors[J]. Nat Rev Dis Primers, 2020, 6(1): 38.
    [14]
    SCHACHTER J, RIBAS A, LONG G V, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)[J]. Lancet, 2017, 390(10105): 1853-1862. doi: 10.1016/S0140-6736(17)31601-X
    [15]
    ZHANG H, DAI Z Y, WU W T, et al. Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer[J]. J Exp Clin Cancer Res, 2021, 40(1): 184. doi: 10.1186/s13046-021-01987-7
    [16]
    ALKHOLIFI F K, ALSAFFAR R M. Dostarlimab an inhibitor of PD-1/PD-L1: a new paradigm for the treatment of cancer[J]. Medicina, 2022, 58(11): 1572. doi: 10.3390/medicina58111572
    [17]
    JANJIGIAN Y Y, SHITARA K, MOEHLER M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial[J]. Lancet, 2021, 398(10294): 27-40.
    [18]
    LI C H, WANG L X, SUN D Q, et al. Colitis induced by PD-1 inhibitor combined with platinum-containing dual drug chemotherapy in Lewis mice and its mechanism[J]. J Cancer Res Ther, 2023, 19(4): 939-944.
    [19]
    MOTZER R, ALEKSEEV B, RHA S Y, et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma[J]. N Engl J Med, 2021, 384(14): 1289-1300.
    [20]
    梁万霞, 赵宇, 廖金花, 等. 信迪利单抗联合阿帕替尼对比阿帕替尼二线治疗晚期食管癌的疗效及安全性[J]. 安徽医学, 2021, 42(5): 530-533.
    [21]
    ZHAO Y S, GUO S P, DENG J, et al. VEGF/VEGFR-targeted therapy and immunotherapy in non-small cell lung cancer: targeting the tumor microenvironment[J]. Int J Biol Sci, 2022, 18(9): 3845-3858.
    [22]
    李加兵, 汤召兵. 基于程序性死亡受体1/程序性死亡受体配体1抑制剂的免疫治疗在晚期肾细胞癌中的研究进展[J]. 癌症进展, 2022, 20(8): 760-765.
    • Related Articles

  • Related Articles

    [1]REN Ke, TIAN Lijun, HUANG Xiaoying, HAN Xudong, ZHANG Ying. Value of indicators including serum neuron-specific enolase in assessing prognosis of patients with cirrhosis complicated by overt hepatic encephalopathy[J]. Journal of Clinical Medicine in Practice, 2024, 28(17): 35-40. DOI: 10.7619/jcmp.20241108
    [2]WANG Hongfang, LI Shuhua, ZHANG Runchun, ZHANG Yanbo. Changes of cellular inflammatory factors, immune levels, myelin basic protein and neuron-specific enolase levels in cerebrospinal fluid in children with benign infantile convulsions with mild gastroenteritis and their clinical significance[J]. Journal of Clinical Medicine in Practice, 2021, 25(11): 54-57, 62. DOI: 10.7619/jcmp.20211644
    [3]YU Xiaochen, Yimamu YIDAYITULA, CAI Ning, ZHANG Yonghui. Dynamic changes of serum neuron-specific enolase in patients with single traumatic subarachnoid hemorrhage and its value in predicting prognosis[J]. Journal of Clinical Medicine in Practice, 2021, 25(11): 8-12. DOI: 10.7619/jcmp.20201422
    [4]FANG Sisi, LUO Lan, ZHOU Haiyin, LONG Caixia. Levels of neuron-specific enolase, myelin basic protein, S-100 protein and their clinical significance in children with viral encephalitis[J]. Journal of Clinical Medicine in Practice, 2020, 24(17): 89-91,95. DOI: 10.7619/jcmp.202017024
    [5]WANG Ying, LIU Min. Value of video electroencephalogram combined with neuron specific enolase detection in the diagnosis of children with febrile convulsions[J]. Journal of Clinical Medicine in Practice, 2020, 24(9): 10-12. DOI: 10.7619/jcmp.202009003
    [6]XUE Yafei, JING Yunyun, ZHANG Yufu. Levels of serum thrombospondin1/2, neuron-specific enolase and S-100β before and after trepanation and drainage in chronic subdural hematoma and their clinical significance[J]. Journal of Clinical Medicine in Practice, 2020, 24(1): 58-61. DOI: 10.7619/jcmp.202001015
    [7]JIA Shujing, SHI Chunxia, LI Lihua. Clinical significance and changes of serum high-sensitivity Creactive protein and neuron-specific enolase in acute cerebral infarction patients with different risk factors[J]. Journal of Clinical Medicine in Practice, 2019, 23(10): 61-64. DOI: 10.7619/jcmp.201910017
    [8]MA Tianming, HAN Xianwei. Change and significance of serum neuron specific enolase level in patients with herpes zoster[J]. Journal of Clinical Medicine in Practice, 2017, (13): 100-102. DOI: 10.7619/jcmp.201713026
    [9]QIU Zhenqin, WANG Bingqiong. Influence of general anesthesia with propofol on serum neuron specific enolase and S100B protein levels and cognitive function in elderly patients[J]. Journal of Clinical Medicine in Practice, 2016, (1): 39-41,55. DOI: 10.7619/jcmp.201601012
    [10]GUO Li-ru, LIU Qing-rui, CHEN Jin-hu. Changes of lysophosphatidic acid, Neuron specific enolase and fibrinogen in patients with progressive cerebral infarction[J]. Journal of Clinical Medicine in Practice, 2010, (15): 17-19,27. DOI: 10.3969/j.issn.1672-2353.2010.15.005

  • Cited by

    Periodical cited type(3)

    1. 赵秀芬，杨名钫，程思思，曾超男，胡秋兰，杨丽珠. E-Coach慢病管理模式在根治性前列腺切除术患者中的应用. 卫生职业教育. 2024(19): 152-156 .
    2. 汤爱玲，许方蕾. 腹腔镜前列腺癌根治术患者出院准备度预警模型的构建. 实用临床医药杂志. 2023(20): 16-20+25 . 本站查看
    3. 张笑，孙健，丁锡奇. 腹腔镜前列腺癌根治术治疗早期前列腺癌对雄激素水平及术后尿失禁发生率的影响. 国际医药卫生导报. 2022(18): 2583-2586 .

    Other cited types(0)

Catalog

    Get Citation
    PDF
    XML
    Article views (62) PDF downloads (15) Cited by(3)
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    © 2020 《实用临床医药杂志》编辑部

    Address: 江苏省扬州市江阳中路136号，扬州大学江阳路北校区14号楼201室China Pos: 225009Tel: 0514-87978917、87978989、87978807

    苏公网安备 32100302010246号

    Supported by: Beijing Renhe Information Technology Co., Ltd.   Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return